OANDP-L
  • Login
No Result
View All Result
The O&P EDGE
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
    • EDGE Flipbooks
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
    • EA Homepage
    • EA Data
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
  • PECOS
  • Magazine
    • Subscription
    • Current Issue
    • Issue Archive
    • News Archive
    • Product & Service Directory
    • Advertising Information
    • EDGE Flipbooks
  • O&P Jobs
    • Find a Job
    • Post a Job
  • EDGE Advantage
    • EA Homepage
    • EA Data
  • O&P Facilities
  • Resources
    • Product & Service Directory
    • Calendar
    • Contact
    • About Us
    • O&P Library
    • The Guide
    • Custom Publications
    • Advertising Information
    • EDGE Direct
    • Amplitude Media Group
No Result
View All Result
The O&P EDGE Magazine
No Result
View All Result
Home News

Targeting Molecules Could Help Find and Kill Cancer Cells

by The O&P EDGE
April 1, 2015
in News
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

For all their lethality, cancer cells don’t look much different from healthy cells, a simple fact that causes endless pain and suffering. Finding cancer cells that have spread and threaten to grow into metastatic tumors is often a life-and-death matter.

Now, a spinoff from the University of Wisconsin-Madison (UW-Madison) called Cellectar Biosciences is developing molecules that bind to more than 60 types of cancer. Several are being tested in early-stage clinical trials. These custom-made molecules can carry either a “flag” that shines brightly in standard medical scanners or a bit of radiation to kill the targeted cancer cells.

These molecules resemble natural components of cell membranes. Once injected intravenously, they are initially taken up throughout the body. Healthy cells break down these agents for elimination, but cancer cells lack that ability and therefore accumulate these molecules.

This phenomenon was recognized in 1970 and preliminary studies were performed at the University of Michigan, where Jamey P. Weichert was a graduate student. He continued these studies when he joined the radiology faculty at UW-Madison in 1998. In 2003, Weichert created Cellectar. Weichert, PhD, is an associate professor and Cellectar’s chief scientific officer.

Cellectar has altered the original molecule to produce a non-toxic agent that adheres tightly to cancer cells, but not to healthy cells. After years of testing, Weichert and colleagues have demonstrated a phospholipid ether (PLE) compound that latches onto at least 60 types of cancer, producing a distinct signal that does not come from normal cells.

In most normal tissues, said Weichert, “there is almost no uptake. If you see a tumor, it shines like a light bulb.”

One of the tags that can be joined to the engineered PLE shows up on PET scans. Another, which shines under near-infrared light, enables surgeons to easily see cancer cells during surgery. When bonded to a small dose of radioactive iodine, the PLE compound becomes a hunter-killer that can, in theory, deliver pinpoint radiation to cancer cells anywhere in the body.

The PLE also enters cancer stem cells, the seeds of resistant cancer cells that often cause a recurrence after treatment, said John Kuo, MD, PhD, an associate professor of neurosurgery at the UW School of Medicine and Public Health. “It was exciting to see that the cancer-selective property of the Cellectar agents also includes cancer stem cells. That’s an important part of not missing cancer cells and achieving long-term cancer control.”

The idea of easily and quickly identifying and treating cancer cells sounds too good to be true, conceded Kuo, who was initially “quite skeptical. So many experimental treatments don’t work in humans or may work against specific cancers or with specific mutations, but are still not effective against cancer stem cells.”

After years of experimenting with PLE in animal models of brain cancer, Kuo is leading a nationwide phase 2 trial to test the timing and dosing of PLE for brain cancer.

Weichert said Cellectar’s compounds are involved in six other early-stage clinical trials. Cellectar agents recently received “orphan drug” status that allows smaller clinical trials and may lead to faster FDA approval.

Despite the gathering momentum for PLE, obstacles remain. Curing cancer in mice is not the same as curing it in people. Even if PLE’s cancer-killing potential does not live up to its billing, the ability to tag individual cancer cells may make it easier for surgeons to detect and remove cancer with even more precision.

“This is on the cusp of being able help surgeons and patients,” said Weichert. “Our job was to make the compounds and turn them over to our clinical colleagues at UW-Madison and elsewhere for testing. We think they will work, but their job is to prove it one way or the other in humans.”

This article was adapted from information provided by UW-Madison.

Related posts:

  1. PLX-PAD: Stem Cell Treatment May Save Limbs
  2. Energy Recycling Foot
  3. Researchers Discover Way to Boost Cancer-Killing Cells
  4. Study Sheds Light on Stem Cell Role in Regenerating Fingers, Toes
Previous Post

UH Researchers Build BMI to Control Prosthetic Hand

Next Post

OPIE Partners with Allard as Integrated Supplier

Next Post

OPIE Partners with Allard as Integrated Supplier

Linkedin X-twitter Facebook

 SUBSCRIBE FOR FREE

 

RECENT NEWS

Get unlimited access!

Join EDGE ADVANTAGE and unlock The O&P EDGE's vast library of archived content.
SUBSCRIBE TODAY

O&P JOBS

Multiple Locations

CERTIFIED ORTHOTIST or PROSTHETIST/ORTHOTIST 

Central

Multiple Locations- Resident Prosthetist / Board Eligible Prosthetist CP/LP

Central

Prosthetic Technician

The O&P EDGE Magazine
 
Required 'Candidate' login to applying this job. Click here to logout And try again
 

Login to your account

  • Forgot Password? | Sign Up

Reset Password

  • Already have an account? Login

Enter the username or e-mail you used in your profile. A password reset link will be sent to you by email.

Signup to your Account

  • By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

    Already have an account? Login

Close
No Result
View All Result
  • PECOS
  • MAGAZINE
    • SUBSCRIBE
    • CURRENT ISSUE
    • ISSUE ARCHIVE
    • NEWS ARCHIVE
    • PRODUCTS & SERVICES DIRECTORY
    • ADVERTISING INFORMATION
  • O&P JOBS
    • FIND A JOB
    • POST A JOB
  • EDGE ADVANTAGE
    • EA Homepage
    • EA Data
  • FACILITIES
  • RESOURCES
    • PRODUCTS & SERVICES DIRECTORY
    • CALENDAR
    • CONTACT
    • ABOUT US
    • O&P LIBRARY
    • THE GUIDE
    • CUSTOM PUBLICATIONS
    • ADVERTISING INFORMATION
    • EDGE DIRECT
    • AMPLITUDE
  • OANDP-L
  • LOGIN

© 2025 The O&P EDGE

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
 

Account Activation

Before you can login, you must activate your account with the code sent to your email address. If you did not receive this email, please check your junk/spam folder. Click here to resend the activation email. If you entered an incorrect email address, you will need to re-register with the correct email address.

 

© 2024 The O&P EDGE

  • About
  • Advertise
  • Contact
  • EDGE Advantage
  • OANDP-L
  • Subscribe

CONTACT US

866-613-0257

[email protected]

201 E. 4th St.
Loveland, CO 80537

The most important industry news and events delivered directly to your inbox every week.

  • About
  • Advertise
  • Contact
  • EDGE Advantage
  • OANDP-L
  • Subscribe

© 2025 The O&P EDGE

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
The O&P EDGE Magazine
 
Required 'Candidate' login to applying this job. Click here to logout And try again
 

Login to your account

  • Forgot Password? | Sign Up

Reset Password

  • Already have an account? Login

Enter the username or e-mail you used in your profile. A password reset link will be sent to you by email.

Signup to your Account

  • By clicking checkbox, you agree to our Terms and Conditions and Privacy Policy

    Already have an account? Login

Close
No Result
View All Result
  • PECOS
  • MAGAZINE
    • SUBSCRIBE
    • CURRENT ISSUE
    • ISSUE ARCHIVE
    • NEWS ARCHIVE
    • PRODUCTS & SERVICES DIRECTORY
    • ADVERTISING INFORMATION
  • O&P JOBS
    • FIND A JOB
    • POST A JOB
  • EDGE ADVANTAGE
    • EA Homepage
    • EA Data
  • FACILITIES
  • RESOURCES
    • PRODUCTS & SERVICES DIRECTORY
    • CALENDAR
    • CONTACT
    • ABOUT US
    • O&P LIBRARY
    • THE GUIDE
    • CUSTOM PUBLICATIONS
    • ADVERTISING INFORMATION
    • EDGE DIRECT
    • AMPLITUDE
  • OANDP-L
  • LOGIN

© 2025 The O&P EDGE

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
 

Account Activation

Before you can login, you must activate your account with the code sent to your email address. If you did not receive this email, please check your junk/spam folder. Click here to resend the activation email. If you entered an incorrect email address, you will need to re-register with the correct email address.